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Multidisciplinary approach a new paradigm for cancer care

M. D. Anderson leads the fight against
bone pain from metastatic cancer
Treatment Update

Nora Janjan is associate
professor in the
Department of
Radiotherapy

Richard Payne is chief of
the Section of Pain and
Symptom Management

Say the word "cancer" and many people think
"pain." It is true that severe pain is a fact for some
cancer patients. The pain is usually caused by the
tumor invading sensitive tissues. The bones are
one of the most common sites of cancer metastasis,
and because of the dense concentration of nerves
around the bones, one of the most painful. But
patients with this metastatic bone pain can now
find relief, thanks to a special clinic recently
launched at The University ofTexas M. D. Anderson Cancer Center.
Metastatic bone pain is often incapacitating.
Patients with this pain are usually unable to care
for themselves, work, drive, or enjoy daily activities. They are dependent on friends and families.
Unfortunately, common cancers such as those of
the prostate, breast, and lung often spread to the
bone, so the problem is widespread .
Patients with metastatic bone pain are treated
with radiation, analgesics, or surgery, usually in
combination. But each patient's pain is different,
and physicians who treat this pain have begun to
realize that an individualized, tailored treatment
strategy works best. Such an approach is possible
only when these specialists come together, sharing
their expertise to evaluate a patient's case and
develop a treatment plan. This multidisciplinary
team approach is helping win the fight against
metastatic bone pain at M. D. Anderson.

~ ~Metastatic bone pain can be controlled
"Relief of metastatic bone pain is a very com plex and difficult clinical problem," said Nora
Janjan, M.D., associate professor in the Department of Radiotherapy and co-founder of the
multidisciplinary metastatic bone pain clinic. "It is
also very costly, to the patients who suffer and are
incapacitated, to the family members who must
stay home and care for the patient, and to society
as a whole, which loses productive people. And

none of this is necessary, because we can control
cancer pain."
By the time patients come to M. D. Ander on
for pain treatment, most have had all of the standard therapies. Their pain often makes the slightest movement distressing. Most were overcome by
the effort of visiting several different clinics: one
for radiotherapy, one for chemotherapy, and others for pain assessment and orthopedic and
neurosurgical evaluations. What was most diffi cult, said Janjan, was that it was sometimes difficult or impossible for these patients to receive their
prescribed radiotherapy because they could not
tolerate the treatment position.
"We're here to heal patients, not hurt them. We
started this multidisciplinary clinic just over a year
ago especially for these patients whose pain is
getting in the way of their treatment," said Janjan.
The clinic is located in the radiotherapy area. For
their initial evaluation, "all the specialists come
together, review the treatment options, develop a
coordinated treatment plan, and present their recommendations to the. patient. The patients stay in
one clinic, eliminating a lot of the moving around
at M. D. Anderson and the travelling back and
forth from home. This is a big relieffor the patients
and for the family members who must accompany
them." The team includes co-founder Richard
Payne, M.D., chief of the Section of Pain and
Symptom Management, Department of NeuroOncology; Herman I. Li6scfiit~~epartment
of Diagnostic Radiology; Donald A. Podoloff,
M.D., Department of Nuclear Medicine; Theresa
Gillis, M.D., Director of Physical Medicine and
Rehabilitation, Department of Neuro-Oncology;
Alan Yasko, M.D., Department of Surgical
Oncology; Samuel Hassenbusch, M.D., Ph.D.,
De.partment of eurosurgery; Richard B. Patt,
M.D., Department of Anesthesiology and Critical
Care; and the medical oncologists on the case.
continued on page 2
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"We have a very practical, effective
strategy for relieving this pain."
The team approach to stopping pain
"Radiation is the standard therapy for metastatic bone pain because it controls the tumor that
is causing the pain," explained Janjan, "but many
other specialists come into play. Dr. Libschitz
helps pinpoint the exact cause and site of the pain,
and Dr. Payne develops strategies to control the
patients' pain so that they can undergo the therapy.
Dr. Podoloff evaluates the extent of bone involvement with bone scans and assesses the potential of
radiopharmaceuticals such as strontium-89 in treating the pain. Dr. Hassenbusch evaluates the utility
of neurosurgical techniques.
"Dr. Yasko and Dr. Gillis are important members of the team because metastasis can weaken the
bones, putting the patients at risk of spinal cord
compression and fractures. Dr. Yasko assesses the
need for surgical stabilization of the bone, which
is often necessary when critical sites like the hip are
involved or if pain persists after radiotherapy. If
surgery is not required, Drs. Yasko and Gillis evaluate ways to reduce the patient's risk of fracture.
"The team approach really works for our pa tients. Our breadth of expertise and coordinated
review of clinical findings allows the team to pick
up subtle signs that one physician alone might
miss. Together, we are able to offer effective interventions."
Of the 2 70 patients who visited the clinic in its
first 14 months, about 60% had their treatment
plan altered after their evaluation. Over 70% had
their pain medications adjusted in some way, usually the schedule or the route of administration.

Current J'y1etastatic Bone Pain Protocols
RT 94-047 ....... A Phase Ill randomized study comparing conventional
palliative radiation (30 Gy /10 fractions) with singlefraction photon radiation (6 or 8 Gy) for bone
metastases in patients receiving systemic therapy
(Study chairman : Dr. Janjan)
RT 94-032 .... ... A Phase Ill randomized study comparing conventional
palliative radiation (30 Gy /10 fractions) with singlefraction photon radiation with or without strontium -89
for painful bone metastases (Study chairman:
Dr. Janjan)
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At the root of the clinic's mission is concern for
patients' quality of life. For these patients whose
cancer has progressed to the point at which it
causes bone pain, a cure is usually· not possible.
"Controlling cancer pain allows us to administer
treatment while improving the patient's functioning and quality oflife," said Janjan. One key to the
team's success is its respect for what the patient can
tell them about his or her pain. She went on., "The
location of their pain reliably tells us where the
disease is, and that guides us in determining which
diagnostic studies need to be done and what kinds
of treatment might be most effective. We listen
very closely to what they say about their symptoms, and once we figure out what is causing these
symptoms, then we have a specific strategy for
managing the pain and the cancer."
Education cuts through barriers to pain
control
Part of the team's role is educating patients and
their families-letting them know that pain is part
of metastatic disease and can be controlled. Patients and their families also learn that it is all right
to be treated with analgesic drugs for cancer pain.
Many people want to avoid strong analgesics such
as morphine. Fear of addiction and a feeling that
these drugs should be "saved" in case the pain gets
worse have led to widespread undertreatment of
cancer pain, reported Payne (see box) .
Janjan and Payne insisted that these myths about
cancer pain must be dispelled. "Most people equate
cancer with suffering," said Janjan. " If we could
eliminate that belief, people would not be afraid to
undergo cancer screening and to find their cancer
earlier, when it can be treated and cured. They
would not be driven to extremes such as suicide
and euthanasia, to relieve their suffering."
The multidisciplinary approach is possible, reported Payne, only where all the specialists are
available under one roof. "I believe the multidisciplinary metastatic bone pain clinic is an absolutely unique resource in this country," he reported.
"I don't think there is any other cancer center that
has a large enough volume of patients to make this
possible. Although metastatic bone pain is very
common, there aren't many centers that have the
local expertise to support such a clinic." He and
other team members have begun videotaping some
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of their cases for educational purposes, and they
\Vill be presenting their experiences at the annual
meetings of the American Society for Clinical
O ncology, the American Pain Society, and the
American Society for Therapeutic Radiology and
Oncology.
Meanwhile, J anjan, Payne, and their colleagues
are conducting research to improve · their treatment of metastatic bone pain. Clinical trials of new
treatments are offered through the clinic. Whether
they receive a standard treatment or an experimental one, however, patients leave the clinic with
so mething many had lost-hope. "The
multidisciplinary clinic is not only good for the
patients, it's good for us who treat the patients.
There's less confusion about each patient's care,

ALL NEW PATIENTS ATM. D. Anderson fill out
a pain inventory. Among patients referred to the
multidisciplinary metastatic bone pain clinic, over
70% reported that they had moderate to severe
pain, and over 25% reported severe pain. Over
half said their pain was not adequately controlled. The undertreatment of cancer pain is
not a myth, said Richard Payne, M.D., co-founder
of the clinic. Many patients fear that the drugs
will lose their effectiveness if used "too soon,"
but the biggest barrier to appropriate drug treatment of cancer pain is fear of addiction.
Studies in thousands of patients at many major
cancer centers have shown that addiction to
pain medications in cancer pain patients is a
nearly nonexistent risk, said Nora Janjan, M.D.,
co-founder of the clinic. "Addiction is a behavior, not a physiologic response," said Janjan.
"What we think of as an addict is someone
whose desire for drugs overwhelms everything
t hey do, how they live. Our patients don't do
that. In fact, once the cause of the pain is treated,
most patients will take themselves off the drugs.
There is something called pseudoaddiction, when
a patient's pain is so severe that he desperately
goes from one physician to another, trying to
get enough medicine to control his pain. Once
he gets adequate medication, that behavior
stops."
Many physicians are not aware that concepts
of cancer pain management have changed in
the last few years and that it is now considered
good medical practice to prescribe drugs such
as morphine for cancer pain. Payne cited cases

because we're a cohesive urut m treating these
patients. We feel we have a very practical, effective
strategy for relieving their pain and making them
comfortable both during and after therapy," said
Janjan. "We believe that controlling the pain while
we control the tumor is absolutely critical."
-KATHRYN L. HALE
REFERRALS. Physicians who have questions or would
like to refer a patient may write Dr. Janjan at the
Department of Radiotherapy (Box 97) or Dr. Payne at
the Department of Neuro-Oncology (Box 100), The
University of Texas M. D. Anderson Cancer Center,
1515 Holcombe Boulevard, Houston, TX 77030, or
call (713) 792 -3432 (Janjan) or 792-2824 (Payne). ■

of patients who lived in fear that their home
town physician would not continue writing prescriptions for their pain medication or that the
local pharmacy would not stock the drugs: For
this reason, he and other members of the multidiscplinary metastatic bone pain team work with
a patient's local physician to develop a treatment plan for the patient. "Once physicians
understand the medical reasons for prescribing
these drugs," said Payne, "they are usually very
willing to continue writing the prescriptions.
The M. D. Anderson physicians will document
our recommendations for drug treatment in the
patient's medical record, giving support should
the local physician's practice be audited by the
Drug Enforcement Administration."
"The State of Texas is unique in this country,"
said Payne, "because, thanks largely to the efforts of Dr. Stratton Hill here at M. D. Anderson,
we have as part of our Medical Practice Act
something called the Intractable Pain Treatment
Act, which reinforces the concept that the
physician's major responsibility is to treat pain
and suffering. and recognizes the legitimacy of
opiate therapy to do that. Each case of suspected abuse is still reviewed separately by the
state Board of Medical Examiners, but physicians in Texas do have legal protection for prescribing these drugs. There's a movement abroad
to go to each state legislature and medical examining board to get similar laws passed in all
states. But this requires education, establishing a
dialogue with the people who make and enforce
the laws."
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Researchers look for markers of cancers and prognosis

Bladder cancer: molecular markers

may guide treatment
Lab to Clinic

H. Barton Grossman is
professor in the
Departments of Urology
and Cell Biology

Jer-Tsong Hsieh is
assistant professor in the
Department of Urology

Cancer cells do not behave like normal cells.
Different genes are activated, and different types
of cancer cells behave differently from each other.
A variety of proteins are produced by cancer cells;
these differ by organ and cell type and by the
extent of the tumor. These characteristic genes
and proteins can be used to identify, or mark,
specific cancers, and much work is being done in
laboratories and clinics to find and identify them.
A marker would be particularly helpful to urologic oncologists in treating patients with bladder
cancer, said H . Barton Grossman, M.D., professor
in the Departments of Urology and Cell Biology
at M. D. Anderson Cancer Center. Grossman hopes
protein or gene markers of bladder cancer will
enable earlier detection and more accurate assessment of patient prognosis.
Grossman and colleague Monica Liebert, Ph.D.,
associate professor in the Departments of Urology
and Cell Biology, began collaborating on bladder
cancer research about 10 years ago at the U niversity of Michigan. They were both interested in the
rnle of monoclonal antibodies in defining new
bladder tumor antigens. "More· recently, we've
both become interested in using molecular techniques to study genes that play key roles in bladder
cancer," Grossman said. They moved their laboratory to M. D. Anderson· about a year ago .
Much oftheir research is funded by the National Cancer Institute~which: has created a cooperative group' called the Bladder Cancer Network
specifically to study bladder cancer markers. M. D.
Anderson is one of six institutions currently involved. Prognostic markers would guide treatment
Bladder cancer, the fifth most common type of
cancer in the United States, has two distinct forms:
superficial disease, which includes early stage, localized cancers, and invasive disease, which includes more advanced tumors or those that have
spread. Most patients have the superficial form of
bladder cancer, which poses little threat of
metastasis. With careful management and close
follow-up, most of these patients do well for long
periods of time. Although they may have recur-
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rences of disease in the bladder, only a small proportion of patients will develop invasive disease.
Patients with the invasive form of bladder cancer have a much greater chance of developing
metastases and eventually dying of their cancer.
Thus, these patients are treated more aggressively,
frequently with resection of the bladder and urinary diversion.
"For both groups of patients, it is very difficult
to tell up front who is going to do well and who
is not," Grossman said. "If we had markers that
would give us that information, we would know
when we could safely lessen the intensity of treatment. For example, patients with superficial bladder cancer whom we knew had a good prognosis
could be treated with endoscopic (transurethral)
resection alone and perhaps wouldn' t need
cystoscopic follow-up quite so often. " Patients
whose tumors were more likely to become invasive
would be treated more aggressively, with intravesical
chemotherapy or immunotherapy, to try to prevent this progression. "Similarly, if we knew which
patients with invasive cancer had a relatively low
chance of developing recurrent can cer and
metastases, they could be treated with cystectomy
alone," Grossman said. Patients at higher risk of
developing metastatic disease would be treated
with aggressive adjunct chemotherapy strategies
to try to prevent the progression.
The current means of predicting outcome lack
precision, Grossman said. Clinical parameters such
as disease stage, tumor grade, and whether tumors
are multifocal are prognostic factors in studies of
groups of patients, but they are not very predictive
for individual patients. For example,most, but not
all, patients with multifocal disease have a cancer
that will probably recur.
Through their work with monoclonal antibodies, Grossman and Liebert have found a marker
that may correlate with survival duration for patients with bladder cancer: a6~4 integrin. Integrins
are transmembrane proteins that act as receptors
for extracellular matrix proteins. a6~4 integrin is
normally expressed only in the basal layer of the
urothelium but seems to be overexpressed in many
bladder cancers. Liebert and Grossman and col-
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leagues examined frozen sections of bladder tu mors, urine specimens, and bladder wash specimens from 59 patients, comparing the a6P4
integrin levels with the patient outcomes. Patients
with the invasive form of cancer ~ho strongly
expressed a6P4 had a significantly shorter survival
time than patients who expressed a6P4 weakly or
not at all. The question remains as to whether this
marker is an independent prognostic indicator;
will it provide more information than clinical indicators such as stage and grade? Answering this
question will be the next step in Grossman and
Liebert's research .
Tumor markers would aid diagnosis
Grossman and Liebert are studying a second
marker, DD23, which appears to be very accurate
for detecting bladder cancer cells in urine and
bladder wash specimens. Unlike integrin a6~4,
whose-level of expression might be helpful in
predicting individual patient outcome, DD23
would be useful in detecting tumors in the first
place. This research is being done in collaboration
with investigators at the University of Oklahoma,
one of the other institutions in the Bladder Cancer
Network. DD23 is essentially not expressed in
normal bladder tissue but is significantly
overexpressed in bladder cancer. "We've seen
DD23 protein expressed in cystectomy specimens
in grossly normal areas of tissue separate from the
tumor," Grossman said. "We think that this may

represent very early neoplastic transformation that
isn't detectable by standard histologic evaluation."
A DD23 test should become commercially available in the future.
Because DD23's expression seems to increase
very early in cancer development, interest has arisen
in testing DD23 as a surrogate end-point marker
in chemoprevention trials. When an agent such as
4-hydroxyphenylretinamide (4-HPR) is tested to
see whether it can help prevent cancer from developing, the classic end points of the trial are tumor
occurrence or recurrence or death. Although these
are clear, objective end points, it can take years to
obtain this information. In fact, the better the
therapy is, the longer it takes to get the results of
the study. The National Cancer Institute is thus
increasingly interested in looking at surrogate
markers for conventional end points. For example,
prostate-specific antigen, or PSA, is being evaluated as a surrogate marker in trials of therapeutic
and chemopreventive agents for prostate cancer.
An upcoming study of 4-HPR in bladder cancer will determine whether a lack of expression of
DD23 correlates with lack ofrecurrence and with
longer survival. "If we can see that an increase in
DD23 expression correlates with tumor recurrence, but appears long before tumor recurrence,
then in future studies we could just look for changes
in DD23," Grossman said. "We could get an
answer in six weeks rather than waiting six months
or several years."
continued on page 7
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Interactive video

continued from page 8

patient educators, and educational specialists. The
presentation combines texts, tables, illustrations,
videos, animation, and music to deliver compre
hensive yet comprehensible messages about breast
cancer.
The videos feature eight women who speak
candidly about their personal experiences with
breast cancer, the surgical treatment options they
chose, and their lives since surgery. "This is prob
ably one of the more popular features of the
system," commented Karen Adsit, Ed.D., Depart
ment of Instructional Development. "For some
patients, the videos are almost like a live discussion
with women who have sur vived. They think 'Here
is a woman who has gone through exactly what
I'm about to go tl1rough.' It's a real person talking
about a real situation, and it is more appealing
than screen after screen of words and pictures."
A range of information offered
The program begins with a general menu that
branches into several subcategories that have even
further ubcategories. The patient can begin witli
any topic he choose and does not have to cycle
through unwanted information. ommenting on
the versatility of the program, Singletary said
"Choices" has a broad appeal. "Different patients
will start out with different levels of knowledge
about breast cancer. Some may be ready to go
straight to the discussion about treatment, whereas

some may need to start with a discussion of the
disease itself. This program is user-driven so the
patient can start where she feels mo t comfortable.
Likewise, the patient can review portions of the
program repeatedly until she gain a comfort level
witl1 a particular topic."
Hands-on, self-paced instruction
Interactive instruction is not new, nor is video
disc technology; however, combinations of tlic e
techniques have only recently been applied within
the medical arena, and tlie "Choices" program i
believed to be among the first of it kind in the
country. According to Singletary, there are a ho t
of benefits to hands-on, self-paced instruction.
"This type of instruction aJlow patients to take
charge of the learning process, which mean they
usually approach the learning ta k more aggres
sively and with a more positive attitude. The infor
mation they gain enables them to formulate
intelligent question when they consult with the
physicians and surgeons."
There are several other benefits to this system.
The information tliat patients receive is consistent,
and the words and visuals used to describe proce
dures are the same all the time; this stimulates
recall. Because tlie patient has to respond physi
cally to make inquirie , she is more apt to retain
information; and because she is operating the sys
tem in total privacy, she does not have to consider
any inquiry " tupid" or feel embarrassed by the
menu topics she chooses to review. These factors
all help the patient learn.
The "Choices" kiosk is conveniently located
witliin tlie breast cancer clinic in an area that
affords tlie patient privacy and a rela.,xed atmo
sphere. A big plus for patients is that the system
is easy to learn. "You don't have to be a computer
expert," commented Adsit. "If you can point and
touch, you can easily operate tliis system." Al
though tlie system was designed primarily for use
by patients, it is also available for family members
and friends. Said Adsit, "The feedback has been
very positive. Patients have commented that tlie
system is easy to use and informative, and tliey
feel better prepared to make decisions when they
consult with the surgeon."
-VICKIE

"Choices: Breast Cancer Treatment Options" was developed by a team including
Dr. Singletary, Dr. Adsit, Dr. Fred Ames, Angela Grays, Alice Judkins, Tim King,
Dr. Stephen Kroll, Ellen Levin, and Susan Peterson.

page 6

J.

WILLIAMS

REFERRALS. Physicians who have questions or would
like to refer a patient may write Dr. Singletary at the
Department of Surgical Oncology (Box 106), The
University of Texas M. D. Anderson Cancer Center,
1515 Holcombe Blvd., Houston, TX 77030, or call
(713) 792-6937.

■
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Bladder cancer
continued from page 5

ddRT-PCR technique isolates genes
expressed in cancer
In addition to monoclonal antibody techniques,
Liebert and Grossman are also using the differential display reverse transcriptase-polymerase chain
reaction (ddRT- PCR) technique to look for genes
whose expression is altered in bladder cancer. Using
this technique, they are comparing genes in undifferentiated and differentiated cells with the same
genetic backgrounds. They have found some novel
genes that seem to be expressed only in differen tiated cells. They also found a gene, called MAL,
that had formerly been thought to be expressed
only in T -lymphocyte cells, not in urothelium.
The next question is, will expression of these genes
be decreased in bladder cancer, in which cells
revert to a less differentiated form? Liebert and
Grossman have found that this is the case with the
MAL gene. T hey are going to continue to study
this gene to see if it has any prognostic significance
in bladder cancer.
"We are hoping to find genes that are interesting from a diagnostic or prognostic standpoint,"
Grossman·said. It is also possible that one of these
genes could eventually be used as a therapeutic
target. "If you have a gene that is expressed in
normal bladder cells but not in bladder cancer
cells, perhaps you could induce reexpression of
that gene in the bladder cancer cells," he said.
"We may not be able to convert a cancer cell to
a normal cell-but if we could convert an aggressive cancer cell to a more benign form, it would
be a significant accomplishment."
Tumor suppressors also targets for gene
therapy
Another M. D. Anderson researcher who is looking for a gene with therapeutic potential in bladder
cancer is Jer-Tsong Hsieh, Ph.D., assistant professor in M. D. Anderson's Urology Research Laboratory. Hsieh and David I. Kleinerman, M.D., an
M. D. Anderson fellow in urology, are assessing
the function of an epithelium-specific cell adhesion molecule, C-CAM, in bladder cancer. Their
studies of this molecule in prostate cancer suggest
that C-CAM is a tumor suppressor whose altered
expression is associated with an early event in
cancer development; C-CAM is expressed at lower
levels in preneoplastic prostate disease and at even
lower levels in prostate cancer than in normal
prostate tissue. Kleinerman and Hsieh found that

introducing C -CAM, in an adenovirus carrier, into
prostate cancer cells in mice suppressed
tumorigenesis. They used an isoform of C-CAM
called C-CAMl.
Since C -CAM is also expressed in normal bladder urothelium, the investigators decided to try
introducing C-CAMl into bladder cancer cells in
mice. As in the prostate, the resulting increased
expression of C-CAMl suppressed tumor growth . .
"Our preliminary data provide compelling evidence that C-CAM suppresses cancer development," Hsieh said. "We want to find out whether
C-CAM could be a candidate for intravesical
therapy." Their next goal is to determine the optimal dosage of the C-CAMl adenovirus for inhibiting bladder cancer growth in mice.
Bladder cancer fascinating model of disease
Bladder cancer is a very good model for experi mental gene therapy, Grossman said. "It's a fascinating model of disease." First, it is a classic
environmentally induced cancer that is clearly associated with carcinogens and smoking. Its behavior fits the model in which a carcinogen is excreted
in the ur~ne and sits in the bladder, causing multifocal disease. Second, the bladder is very accessible; it can be easily studied, and agents can be
easily applied to the urothelial surface through a
catheter.
In addition to working in the laboratory,
Grossman is also the director of clinical research in
the Department of Urology. "One of my goals
here is to foster and develop the clinical research
protocols at M. D. Anderson, to try to bring the
laboratory advances and clinical medicine together,"
he says. He and Liebert continue to look at the
tumor tissue specimens from his patients in search
of markers that will determine each patient's prognosis. "We hope to develop some novel treatment
strategies based on these prognostic markers," he
said. "We think they will show us which patients
need aggressive therapy and which don't."
~SUNITA PATTERSON
REFERRALS. Physicians who have questions or would
like to refer a patient may write Dr. Grossman at the
Department of Urology, Box ll0, The University of
Texas M. D. Anderson Cancer Center, 1515 Halcom be
Blvd., Houston, TX 77030, or call (713) 792-3250. ■
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Interactive computer technology puts information at patients' fingertips

New computer program enhances the
surgeon-patient consultation
Patient Education

Eva Singletary is chief of
breast surgery,
Department of Surgical
Oncology

More than 850 women undergo surgery for
breast cancer at The University of Texas M. D.
Anderson Cancer Center each year. & part of the
standard procedure, each surgery candidate spends
several hours in consultations with surgeons and
other health c~e professionals reviewing treatment options, surgical procedures, and associated
risks. The goal is to provide each patient with the
information she needs when deciding which procedure is best for her, said Eva Singletary, M.D.,
chief of breast surgery at M. D. Anderson, but
often the stress associated with a diagnosis of
breast cancer and impending surgery is compounded by the frustration of having to deal with
mountains of complex medical information. "It
can be quite a shock for a woman to learn she has
breast cancer," said Singletary. "Her anxiety becomes even worse when she has to decide how to
combat the disease."
In early 1994, the breast cancer staff at M. D.
Anderson began considering ways to streamline
the consultation process while improving its efficiency and ensuring that patients were well in-

formed. Their solution was an inno ati computer system recently put into plac at th c nter.
The system offers user-dri n, lf-pac d in truction ba.s ed on interacti e vid odi c t hnol
.B
touching the sere n, pati nt can h
range of information ab ut br a t
system literall puts informati nab ut br a t ancer at th patient' fing rtip and pr nt 1t m an
appealing mann r that moti at th p ti nt rath r
than intimidating h r.
"We d
loped thi
tern t h lp all ·at
some of the fear as ociat d with th di gno i and
to enable breast cancer pati nt to mak informed
decisions, with the surg on about urgical treatment options ' Singletary plain d.

Program includes videos of eight patients
The computerized s stem can be operated hile
standing or sitting and operate b touch command, much like an ATM machine. The multimedia program entitled Choices: Brea t Cancer
Treatment Options \J as de eloped through the
cooperati e efforts of patients surgeons nurses
continued on page 6

